Market Overview

UPDATE: Canaccord Genuity Downgrades Meridian Bioscience to Hold on FQ3 Report


Canaccord Genuity reduced its rating on Meridian Bioscience (NASDAQ: VIVO) from Buy to Hold and cut its price target from $25 to $18.

Canaccord Genuity commented, "We are downgrading our rating on VIVO to HOLD from Buy following a FQ3 miss, lower F2012 guidance, and our concerns on modest growth through next year. We lower our price target to $18 from $25. … Although the comp was tough in the quarter, we are more concerned about structural challenges. VIVO's C. difficile immunoassay business continues to face competitive pressures (mainly Alere), its sales force struggles defending share, and Illumigene utilization should be more robust with ~900 customers."

Meridian Bioscience closed at $16.81 on Thursday.

Latest Ratings for VIVO

May 2019MaintainsSellSell
May 2019UpgradesUnderweightNeutral
Apr 2019DowngradesHoldSell

View More Analyst Ratings for VIVO
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (VIVO)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Chuy's Holdings Sold 6.7M Shares in Offering for $79.6M

UPDATE: Deutsche Bank Lowers PT on Molina Healthcare from $23 to $22